Celltrion’s ‘Remsima’ to expand into Middle Eastern market, starting with Saudi Arabia
Celltrion acquired approval to sell Remsima from the Saudi Arabian regulatory authority, the Saudi FDA(Saudi Food and Drug Authority), on the 20th of April, and begun the sales from the 19th of Mar.
On a basis of the Saudi Arabian approval, its sales approval procedure in the member countries of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
